Mikami R, Hiraga Y, Yotsumoto H, Osada H
Z Erkr Atmungsorgane. 1977 Aug;149(3):415-22.
The parenteral use of triamcinolone acetonide (Kenacort A) is said to have the following advantages: to keep the effect for two weeks by one injection, to be able to reduce the total treatment dosage and to secure the dosage regardless of patients cooperation. From these reasons, a trial of the Kenacort A treatment was made for 40 cases with sarcoidosis by 7 times of intramuscular injection at two-week intervals: 80 mg each at the 1st and 2nd and 40 mg at the 3rd to 7th. The results were compared with the already reported double blind trial using the oral initial dosage of 30 mg of prednisolone followed by a a reduced dosage for a period of 6 months. This paper will give an interim report of the 4 month follow-up after the ceasation of treatment. The results showed: 1. the disappearance rate of chest findings, either BHL or parenchymal pulmonary lesions, was higher in this trial than the above-mentioned oral treatment, 2. the high rate of improvement was found in ocular lesion, and 3. side effects were less in this trial than the oral treatment.
据说曲安奈德（康宁克通A）的肠胃外给药有以下优点：一次注射药效可维持两周，能够减少总治疗剂量，并且无论患者是否配合都能确保剂量。基于这些原因，对40例结节病患者进行了康宁克通A治疗试验，每隔两周进行7次肌肉注射：第1次和第2次各注射80毫克，第3次至第7次各注射40毫克。将结果与已报道的双盲试验进行比较，该试验口服泼尼松龙初始剂量为30毫克，随后在6个月内逐渐减量。本文将给出治疗停止后4个月随访的中期报告。结果显示：1. 本试验中胸部表现（双侧肺门淋巴结肿大或实质性肺部病变）的消失率高于上述口服治疗；2. 眼部病变的改善率较高；3. 本试验的副作用比口服治疗少。
